Literature DB >> 26857854

Methylation-based classification of benign and malignant peripheral nerve sheath tumors.

Manuel Röhrich1,2, Christian Koelsche1,2, Daniel Schrimpf1,2, David Capper1,2, Felix Sahm1,2, Annekathrin Kratz1,2, Jana Reuss2, Volker Hovestadt3, David T W Jones4, Melanie Bewerunge-Hudler5, Albert Becker6, Joachim Weis7, Christian Mawrin8, Michel Mittelbronn9,10, Arie Perry11, Victor-Felix Mautner12, Gunhild Mechtersheimer13, Christian Hartmann14, Ali Fuat Okuducu15, Mirko Arp16, Marcel Seiz-Rosenhagen16, Daniel Hänggi16, Stefanie Heim17, Werner Paulus17, Jens Schittenhelm18, Rezvan Ahmadi19, Christel Herold-Mende19, Andreas Unterberg19, Stefan M Pfister4,20, Andreas von Deimling1,2, David E Reuss21,22.   

Abstract

The vast majority of peripheral nerve sheath tumors derive from the Schwann cell lineage and comprise diverse histological entities ranging from benign schwannomas and neurofibromas to high-grade malignant peripheral nerve sheath tumors (MPNST), each with several variants. There is increasing evidence for methylation profiling being able to delineate biologically relevant tumor groups even within the same cellular lineage. Therefore, we used DNA methylation arrays for methylome- and chromosomal profile-based characterization of 171 peripheral nerve sheath tumors. We analyzed 28 conventional high-grade MPNST, three malignant Triton tumors, six low-grade MPNST, four epithelioid MPNST, 33 neurofibromas (15 dermal, 8 intraneural, 10 plexiform), six atypical neurofibromas, 43 schwannomas (including 5 NF2 and 5 schwannomatosis associated cases), 11 cellular schwannomas, 10 melanotic schwannomas, 7 neurofibroma/schwannoma hybrid tumors, 10 nerve sheath myxomas and 10 ganglioneuromas. Schwannomas formed different epigenomic subgroups including a vestibular schwannoma subgroup. Cellular schwannomas were not distinct from conventional schwannomas. Nerve sheath myxomas and neurofibroma/schwannoma hybrid tumors were most similar to schwannomas. Dermal, intraneural and plexiform neurofibromas as well as ganglioneuromas all showed distinct methylation profiles. Atypical neurofibromas and low-grade MPNST were indistinguishable with a common methylation profile and frequent losses of CDKN2A. Epigenomic analysis finds two groups of conventional high-grade MPNST sharing a frequent loss of neurofibromin. The larger of the two groups shows an additional loss of trimethylation of histone H3 at lysine 27 (H3K27me3). The smaller one retains H3K27me3 and is found in spinal locations. Sporadic MPNST with retained neurofibromin expression did not form an epigenetic group and most cases could be reclassified as cellular schwannomas or soft tissue sarcomas. Widespread immunohistochemical loss of H3K27me3 was exclusively seen in MPNST of the main methylation cluster, which defines it as an additional useful marker for the differentiation of cellular schwannoma and MPNST.

Entities:  

Keywords:  450k; Atypical neurofibroma; Clone NFC; Ganglioneuroma; H3K27me3; MPNST; Methylation; NF1; PRC2; Peripheral nerve sheath tumor; Schwannoma

Mesh:

Substances:

Year:  2016        PMID: 26857854     DOI: 10.1007/s00401-016-1540-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  57 in total

1.  Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors.

Authors:  Melike Pekmezci; Areli K Cuevas-Ocampo; Arie Perry; Andrew E Horvai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics.

Authors:  Felix K F Kommoss; Damian Stichel; Daniel Schrimpf; Mark Kriegsmann; Basile Tessier-Cloutier; Aline Talhouk; Jessica N McAlpine; Kenneth T E Chang; Dominik Sturm; Stefan M Pfister; Laura Romero-Pérez; Thomas Kirchner; Thomas G P Grünewald; Rolf Buslei; Hans-Peter Sinn; Gunhild Mechtersheimer; Peter Schirmacher; Dietmar Schmidt; Hans-Anton Lehr; Felix Sahm; David G Huntsman; C Blake Gilks; Friedrich Kommoss; Andreas von Deimling; Christian Koelsche
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-25       Impact factor: 4.553

3.  Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.

Authors:  John B Wojcik; Dylan M Marchione; Simone Sidoli; Anissa Djedid; Amanda Lisby; Jacek Majewski; Benjamin A Garcia
Journal:  Cancer Res       Date:  2019-03-21       Impact factor: 12.701

4.  Comparision of New Diagnostic Tools for Malignant Peripheral Nerve Sheath Tumors.

Authors:  Ayca Ersen; Melike Pekmezci; Andrew L Folpe; Tarik Tihan
Journal:  Pathol Oncol Res       Date:  2016-10-12       Impact factor: 3.201

5.  Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.

Authors:  Sophie Le Guellec; Nicolas Macagno; Valérie Velasco; Laurence Lamant; Marick Lae; Thomas Filleron; Nausicaa Malissen; Elisabeth Cassagnau; Philippe Terrier; Christine Chevreau; Dominique Ranchere-Vince; Jean-Michel Coindre
Journal:  Mod Pathol       Date:  2017-07-28       Impact factor: 7.842

6.  Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.

Authors:  Adriana Olar; Khalida M Wani; Charmaine D Wilson; Gelareh Zadeh; Franco DeMonte; David T W Jones; Stefan M Pfister; Erik P Sulman; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2017-01-27       Impact factor: 17.088

7.  Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs.

Authors:  Sabrina Rossi; Daniela Gasparotto; Matilde Cacciatore; Marta Sbaraglia; Alessia Mondello; Maurizio Polano; Alessandra Mandolesi; Alessandro Gronchi; David E Reuss; Andreas von Deimling; Roberta Maestro; Angelo Paolo Dei Tos
Journal:  Mod Pathol       Date:  2017-09-01       Impact factor: 7.842

8.  Low-grade Schwann cell neoplasms with leptomeningeal dissemination: clinicopathologic and autopsy findings.

Authors:  Erika F Rodriguez; Jaishri Blakeley; Shannon Langmead; Alessandro Olivi; Anthony Tufaro; Abeer Tabbarah; Gail Berkenblit; Justin M Sacks; Scott D Newsome; Elizabeth Montgomery; Fausto J Rodriguez
Journal:  Hum Pathol       Date:  2016-09-22       Impact factor: 3.466

9.  Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

Authors:  Michael W Ronellenfitsch; Patrick N Harter; Martina Kirchner; Christoph Heining; Barbara Hutter; Laura Gieldon; Jens Schittenhelm; Martin U Schuhmann; Marcos Tatagiba; Gerhard Marquardt; Marlies Wagner; Volker Endris; Christian H Brandts; Victor-Felix Mautner; Evelin Schröck; Wilko Weichert; Benedikt Brors; Andreas von Deimling; Michel Mittelbronn; Joachim P Steinbach; David E Reuss; Hanno Glimm; Albrecht Stenzinger; Stefan Fröhling
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 10.  Genetic Events and Signaling Mechanisms Underlying Schwann Cell Fate in Development and Cancer.

Authors:  Harish N Vasudevan; Calixto-Hope G Lucas; Javier E Villanueva-Meyer; Philip V Theodosopoulos; David R Raleigh
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.